Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
May 2019
-
Media ReleaseNovartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MSData from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent® (siponimod) had a meaningful benefit on cognitive…
-
Media ReleaseNew AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing…
-
Media ReleaseNovartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MSUp to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or…
-
Media ReleaseAveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patientsInterim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101…
-
Media ReleaseNovartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AANAfter long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study…
April 2019
-
Media ReleaseNew data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditionsNovartis leads the way at AAN with 52 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple…
-
Media ReleaseSandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumorsCollaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement,…
-
Key ReleaseNovartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgradedTransformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by…
-
Key ReleaseNovartis entame 2019 avec une forte croissance des ventes et une hausse à deux chiffres du résultat opérationnel core[1], le lancement de Mayzent et le spin-off d'Alcon; profit annuel revu à la hausseLa transformation en une société axée sur les médicaments a continué avec le spin-off d'Alcon; les commentaires ci-après ne concernent que les activités poursuivies[2] Chiffre d'affaires net des…
-
Key ReleaseNovartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehobenDie Transformation zu einem fokussierten Arzneimittelunternehmen schreitet mit der Abspaltung von Alcon voran; die folgenden Angaben beziehen sich auf die fortzuführenden Geschäftsbereiche[2]…
-
Media ReleaseAveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human…
-
Media ReleaseNovartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMDBy 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER…
Pagination
- ‹ Previous page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- …
- 100
- › Next page